Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$8.53
-0.4%
$6.79
$4.80
$18.13
$326.48M1.39568,931 shs969,530 shs
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
$5.09
-0.2%
$5.96
$3.85
$8.75
$409.06M1.3363,392 shs706,141 shs
Oculis Holding AG stock logo
OCS
Oculis
$19.89
+4.6%
$17.89
$10.79
$23.08
$868.44M0.2743,949 shs66,080 shs
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
$5.78
-9.0%
$5.36
$3.90
$14.67
$410.89M1.37656,905 shs1.17 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-0.35%+2.16%+16.05%+20.65%-51.75%
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
-0.20%-7.45%-24.03%-30.37%-3.78%
Oculis Holding AG stock logo
OCS
Oculis
+4.63%+13.01%+17.00%-3.26%+67.85%
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
-8.98%+1.94%+13.33%-30.36%-32.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
3.2536 of 5 stars
4.21.00.00.03.53.30.6
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
4.5523 of 5 stars
3.53.00.04.81.92.51.9
Oculis Holding AG stock logo
OCS
Oculis
2.6062 of 5 stars
3.55.00.00.02.70.00.6
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
3.9349 of 5 stars
3.52.00.04.32.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
2.43
Hold$17.86109.35% Upside
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
3.00
Buy$24.00371.51% Upside
Oculis Holding AG stock logo
OCS
Oculis
3.00
Buy$31.5058.37% Upside
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
3.00
Buy$19.17231.60% Upside

Current Analyst Ratings Breakdown

Latest ITOS, OCS, ORIC, and MGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$16.00 ➝ $13.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$12.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$16.00 ➝ $12.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$47.00 ➝ $9.00
5/14/2025
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $35.00
5/13/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$15.00 ➝ $8.00
5/9/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$28.00 ➝ $33.00
5/6/2025
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $12.00
5/6/2025
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$35M9.33N/AN/A$16.08 per share0.53
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
$34.51M11.85N/AN/A$2.17 per share2.35
Oculis Holding AG stock logo
OCS
Oculis
$980K886.16N/AN/A$2.87 per share6.93
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
N/AN/AN/AN/A$3.42 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$112.64M-$3.04N/AN/AN/AN/A-20.11%-17.50%8/14/2025 (Estimated)
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
-$84.03M-$2.32N/A13.390.37-633.05%-146.38%-53.05%8/11/2025 (Estimated)
Oculis Holding AG stock logo
OCS
Oculis
-$98.92M-$2.64N/AN/AN/A-8,043.28%-71.31%-56.85%N/A
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
-$100.70M-$1.87N/AN/AN/AN/A-44.54%-40.72%8/11/2025 (Estimated)

Latest ITOS, OCS, ORIC, and MGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million
5/8/2025Q1 2025
Oculis Holding AG stock logo
OCS
Oculis
-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million
5/5/2025Q1 2025
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
-$0.51-$0.42+$0.09-$0.42N/AN/A
4/28/2025Q1 2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$0.94-$0.80+$0.14-$0.80$9.35 millionN/A
3/13/2025Q4 2024
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
-$0.48-$0.50-$0.02-$0.50$1.50 million$21.39 million
3/11/2025Q4 2024
Oculis Holding AG stock logo
OCS
Oculis
-$0.48-$0.76-$0.28-$0.76$0.21 millionN/A
3/5/2025Q4 2024
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$1.14-$1.01+$0.13-$1.01N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/AN/AN/AN/AN/A
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Oculis Holding AG stock logo
OCS
Oculis
N/AN/AN/AN/AN/A
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/A
14.80
14.80
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
0.86
2.34
2.34
Oculis Holding AG stock logo
OCS
Oculis
0.01
4.02
4.02
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
N/A
10.56
13.15

Institutional Ownership

CompanyInstitutional Ownership
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
97.16%
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
67.48%
Oculis Holding AG stock logo
OCS
Oculis
22.30%
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
95.05%

Insider Ownership

CompanyInsider Ownership
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
12.50%
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
7.50%
Oculis Holding AG stock logo
OCS
Oculis
N/A
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
6.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
9038.27 million31.97 millionOptionable
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
30080.37 million71.59 millionOptionable
Oculis Holding AG stock logo
OCS
Oculis
243.66 millionN/ANot Optionable
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
8071.09 million67.09 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
iTeos Therapeutics stock logo

iTeos Therapeutics NASDAQ:ITOS

$8.53 -0.03 (-0.35%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$8.44 -0.09 (-1.06%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$5.09 -0.01 (-0.20%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$5.01 -0.08 (-1.47%)
As of 05/27/2025 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Oculis stock logo

Oculis NASDAQ:OCS

$19.89 +0.88 (+4.63%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$19.86 -0.03 (-0.13%)
As of 05/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

ORIC Pharmaceuticals stock logo

ORIC Pharmaceuticals NASDAQ:ORIC

$5.78 -0.57 (-8.98%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$5.90 +0.13 (+2.16%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.